HOME >> BIOLOGY >> NEWS
Epimmune scientists report positive pre-clinical data on vaccine designed to combat HIV's ability to mutate

Company on track to initiate clinical trials late this year or early 2002 of epitope-based vaccine for the prevention and treatment of HIV

Keystone, CO, April 2, 2001 - Epimmune Inc. (Nasdaq: EPMN) today announced positive pre-clinical data on its HIV vaccine that is designed to directly address the problem of viral mutation. At the Keystone Symposium: "AIDS Vaccines in the New Millennium" on March 30, 2001 in Keystone, Colorado, Company scientists reported that the vaccine stimulated multiple anti-HIV cytotoxic T-cell immune responses in animal models. Epimmune has begun manufacturing the vaccine for human testing and plans to initiate clinical trials late this year or early 2002 in both non-infected volunteers and in individuals infected with HIV.

The current standard HIV therapy for Americans is a three-drug anti-retroviral combination that costs approximately $15,000 per year. While anti-retroviral drugs are effective at suppressing HIV replication in infected individuals, they do not eliminate the infection and have toxic side effects that impede their long-term use. A vaccine that can provide both preventative and therapeutic benefits has great potential to help control the AIDS epidemic and curtail the costs and side effects of anti-retroviral therapies.

"A major challenge to the development of an effective AIDS vaccine is the ability of HIV to mutate. Epimmunes vaccine is designed to directly address this problem," said Mark Newman, Ph.D., Vice President of the Infectious Disease Program at Epimmune. "One of the unique features of Epimmunes vaccine is that it is composed of epitopes, or protein fragments, which are strategically selected from non-mutating regions of HIV. As a result, it is expected to be harder for the virus to develop variants that can escape the vaccine-induced immune response."

Strong cellular immunity is characteristic of long-term non-progressors or HIV-positive individuals
'"/>

Contact: Laura Hansen
lhansen@irpr.com
858-860-0266
Epimmune, Inc.
1-Apr-2001


Page: 1 2

Related biology news :

1. DNA lends scientists a hand, revealing new chemical reactions
2. Conference at UH opens doors for new scientists, engineers
3. Wisconsin scientists develop quick botox test
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Alaska scientists find Arctic tundra yields surprising carbon loss
6. UAF scientists discover new marine habitat in Alaska
7. Information system to help scientists analyze mechanisms of social behavior
8. Zoonotic diseases - European scientists unite to fight diseases
9. Israeli scientists reveal the plan of a key cellular machine
10. Study by Israeli scientists provides insight on DNA code
11. Computer scientists at UH developing nurturing computers

Post Your Comments:
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/15/2014)... a non-traditional biophysics textbook and it describes how life ... of discovery into biological systems and provides an understanding ... is about how our genes make proteins that control ... cells in an organism. It quantifies the principles of ... be found on both large and small scales. The ...
(Date:10/15/2014)... Fred Alt will be awarded the 44th Rosenstiel Award ... for his pioneering research exploring the mechanisms of genomic ... cancer cells. Alt is the second alumnus to win ... Nobel Prize in 2003. , Alt is the Charles ... at Harvard Medical School and an investigator at the ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
(Date:10/22/2014)... -- Research and Markets  has announced the addition ... Application, Geography - Global Analysis and Forecast (2014 - ... Organic electronics, also called as polymer electronics or plastic ... with small conductive molecules and electrically conductive polymers. It ... are carbon based, made using synthetic strategies developed in ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Sidney Kimmel Cancer Center at Thomas Jefferson University ... , Through the Strategic Alliance Partnership program, the ... will collaborate to raise awareness of the Center’s ... and other projects. Clinicians and other health care ...
(Date:10/19/2014)... 2014 NextCODE Health, which enables clinicians and researchers ... time, today announced the launch of its new genomic data ... the American Society of Human Genetics (ASHG) annual meeting in ... up and apply for free beta access, visit www.nextcode.com ... can be viewed here . The Exchange: ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
Cached News: